PharmaBlock Sciences (Nanjing), Inc.

SZSE:300725 Stock Report

Market Cap: CN¥7.0b

PharmaBlock Sciences (Nanjing) Management

Management criteria checks 3/4

PharmaBlock Sciences (Nanjing)'s CEO is Minmin Yang, appointed in Apr 2023, has a tenure of 1.67 years. directly owns 20.82% of the company’s shares, worth CN¥1.45B. The average tenure of the management team and the board of directors is 1.8 years and 3.1 years respectively.

Key information

Minmin Yang

Chief executive officer

CN¥860.0k

Total compensation

CEO salary percentagen/a
CEO tenure1.7yrs
CEO ownership20.8%
Management average tenure1.8yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

PharmaBlock Sciences (Nanjing) (SZSE:300725) Takes On Some Risk With Its Use Of Debt

Nov 22
PharmaBlock Sciences (Nanjing) (SZSE:300725) Takes On Some Risk With Its Use Of Debt

PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) P/E Is Still On The Mark Following 40% Share Price Bounce

Sep 30
PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) P/E Is Still On The Mark Following 40% Share Price Bounce

PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Aug 23
PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Sluggish Earnings Might Be Just The Beginning Of Its Problems

We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt

Jul 31
We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt

PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31

Jun 12
PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31

PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Apr 21
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump

Mar 07
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump

CEO

Minmin Yang (52 yo)

1.7yrs

Tenure

CN¥860,000

Compensation

Dr. Minmin Yang, Ph D., serves as Director of Myrobalan Therapeutics Holding, Inc. He is Co-Founder at PharmaBlock Sciences (Nanjing), Inc and has been its Chairman since December 2014. Dr. Yang serves as...

Leadership Team

NamePositionTenureCompensationOwnership
Minmin Yang
Co-Founder1.7yrsCN¥860.00k20.82%
CN¥ 1.5b
Wu Yifei
Secretary3.5yrsCN¥1.05mno data
Shijie Zhang
Chief Technology Officer1.9yrsCN¥2.29m0.020%
CN¥ 1.4m
Jing Li
Sr. VP of Process Chemistry & President of PharmaBlock (USA)no dataCN¥1.97mno data
Shuhai Zhao
Co-founder & Chief Scientific Officerno dataCN¥344.50kno data
David Chen
Executive VPless than a yearno datano data
Dezhi Sha
Sr. VP of Process Technology & Manufacturingno datano datano data

1.8yrs

Average Tenure

52yo

Average Age

Experienced Management: 300725's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Minmin Yang
Co-Founder10yrsCN¥860.00k20.82%
CN¥ 1.5b
Yuanping Jie
Non-Independent Directorno dataCN¥710.00kno data
Shanbao Yu
Non-Employee Supervisor3.1yrsCN¥747.60kno data
Shuqiang Zhang
Non-Employee Supervisor3.1yrsno datano data
Jingwei Zhu
Director3.1yrsCN¥1.02mno data
Li Jin
Non-Employee Supervisor & Independent Director3.1yrsCN¥80.00kno data
Xiaonan Zheng
Independent Directorno datano datano data
Chen Chen
Non-Independent Directorno datano datano data
Xihe Jiang
Independent Directorno datano datano data

3.1yrs

Average Tenure

46.5yo

Average Age

Experienced Board: 300725's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 09:37
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaBlock Sciences (Nanjing), Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.
Yuan Yuan SunIndustrial Securities Co. Ltd.